Logo

Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma

Share this
Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma

Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma

Shots:

  • The P-III LIBERTY ASTHMA VOYAGE Trial evaluates Dupixent (100/200mg- q2w) + SoC in 408 children aged 6-11yrs. with uncontrolled mod. to sev. asthma
  • The results showed a 65% avg. reduction in the rate of severe asthma attacks @1yrs.; improvement in lung function by 5.32% points @ 12wks. & as early as 2wks. & sustained for ~52wks- improved asthma control @24wks.; improvement on disease symptoms & impact (81% vs 64%) as measured by ≥0.5 improvements on a 7-point scale
  • The safety results were consistent with the known safety profile of Dupixent in patients aged ≥12yrs. The therapy is currently under regulatory review in the EU & other authorities globally for children aged 6 to 11yrs.

click here ­to­ read full press release/ article | Ref: PRNewswire| Image: Sanofi


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family